Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Teva
UBS
Chubb
Argus Health
Express Scripts
McKinsey
Cantor Fitzgerald
Harvard Business School

Generated: February 21, 2019

DrugPatentWatch Database Preview

Genus Lifesciences Company Profile

« Back to Dashboard

What is the competitive landscape for GENUS LIFESCIENCES, and what generic alternatives to GENUS LIFESCIENCES drugs are available?

GENUS LIFESCIENCES has nine approved drugs.

There are seven US patents protecting GENUS LIFESCIENCES drugs.

There are forty-three patent family members on GENUS LIFESCIENCES drugs in twenty-three countries and nineteen supplementary protection certificates in ten countries.

Summary for Genus Lifesciences
International Patents:43
US Patents:7
Tradenames:8
Ingredients:8
NDAs:9

Drugs and US Patents for Genus Lifesciences

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genus Lifesciences YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No 6,926,907 ➤ Sign Up Y ➤ Sign Up
Genus Lifesciences LEVOLET levothyroxine sodium TABLET;ORAL 021137-007 Jun 6, 2003 DISCN No No ➤ Sign Up ➤ Sign Up
Genus Lifesciences LEVOLET levothyroxine sodium TABLET;ORAL 021137-001 Jun 6, 2003 DISCN No No ➤ Sign Up ➤ Sign Up
Genus Lifesciences LEVOLET levothyroxine sodium TABLET;ORAL 021137-011 Jun 6, 2003 DISCN No No ➤ Sign Up ➤ Sign Up
Genus Lifesciences YOSPRALA aspirin; omeprazole TABLET, DELAYED RELEASE;ORAL 205103-001 Sep 14, 2016 RX Yes No 9,364,439 ➤ Sign Up Y ➤ Sign Up
Genus Lifesciences LEVOLET levothyroxine sodium TABLET;ORAL 021137-006 Jun 6, 2003 DISCN No No ➤ Sign Up ➤ Sign Up
Genus Lifesciences LEVOLET levothyroxine sodium TABLET;ORAL 021137-004 Jun 6, 2003 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GENUS LIFESCIENCES drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 81 mg/40 mg ➤ Subscribe 2016-10-14

International Patents for Genus Lifesciences Drugs

Country Document Number Estimated Expiration
Norway 20035275 ➤ Sign Up
Norway 333836 ➤ Sign Up
Eurasian Patent Organization 028049 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2013101897 ➤ Sign Up
Mexico 2011002515 ➤ Sign Up
Japan 2004536809 ➤ Sign Up
Mexico 2014007935 ➤ Sign Up
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Genus Lifesciences Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/028 United Kingdom ➤ Sign Up PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
C/GB08/020 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
C0025 Belgium ➤ Sign Up PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
C0026 France ➤ Sign Up PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
C0038 France ➤ Sign Up PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
C/GB10/012 United Kingdom ➤ Sign Up PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112
C/GB98/031 United Kingdom ➤ Sign Up PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Cantor Fitzgerald
Express Scripts
Fuji
McKinsey
US Department of Justice
Deloitte
Federal Trade Commission
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.